Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

PARP inhibitors (PARPis) have clinical efficacy in BRCA-deficient cancers, but not BRCA-intact tumors, including glioblastoma (GBM). We show that MYC or MYCN amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARPi via Myc-mediated transcriptional repressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Jian-Fang, Stanciu, Monica, Humphrey, Melissa R., Gorham, Joshua, Wakimoto, Hiroko, Nishihara, Reiko, Lees, Jacqueline, Zou, Lee, Martuza, Robert L., Wakimoto, Hiroaki, Rabkin, Samuel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606647/
https://www.ncbi.nlm.nih.gov/pubmed/31266951
http://dx.doi.org/10.1038/s41467-019-10993-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606647/
https://www.ncbi.nlm.nih.gov/pubmed/31266951
http://dx.doi.org/10.1038/s41467-019-10993-5

Ejemplares similares